Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry

• Published in: Thrombosis research 2011-02, Vol.127, p.S1-S4
• Main Authors: Trujillo-Santos, Javier, Casa, José Manuel, Casado, Ignacio, Samperiz, Ángel Luis, Quintavalla, Roberto, Sahuquillo, Joan Carles, Monreal, Manuel
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Anticoagulants - therapeutic use; Cancer; Female; Hematology, Oncology and Palliative Medicine; Hemorrhage - mortality; Humans; Middle Aged; Mortality; Neoplasms - complications; Neoplasms - mortality; Prospective Studies; Pulmonary Embolism - mortality; Registries; Treatment Outcome; Venous thromboembolism; Venous Thromboembolism - complications; Venous Thromboembolism - mortality; Women
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/S0049-3848(11)00006-5

Abstract The influence of the site of cancer on outcome in cancer women with venous thromboembolism (VTE) is poorly understood. Reliable information on its influence might facilitate better use of prevention strategies. We assessed the 30-day outcome in all women with active cancer in the RIETE Registry, trying to identify if differences exist according to the tumor site. Up to May 2010, 2474 women with cancer and acute VTE had been enrolled. The most common sites were the breast (26%), colon (13%), uterus (9.3%), and haematologic (8.6%) cancers. During the 30-day study period, 329 (13%) patients died. Of them, 71 (2.9%) died of pulmonary embolism (PE), 22 (0.9%) died of bleeding. Fatal PE was more common in women with breast, colorectal, lung or pancreatic cancer (59% of the fatal PEs). Fatal bleeding was more frequent in women with colorectal, haematologic, ovarian cancer or carcinoma of unknown origin (55% of fatal bleedings).